Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
01:40pm, Monday, 27'th Jan 2025
EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the a
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination wi
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine t
Revenues, Treatment Pipeline Driving Exelixis Higher
07:44am, Wednesday, 22'nd Jan 2025
Shares of oncology company Exelixis, Inc. (EXEL) gaining on rising revenue, pipeline progress.
EXEL vs. TECH: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 21'st Jan 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Techne (TECH). But which of these two companies is the best option for those looking for u
4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility
10:36am, Tuesday, 21'st Jan 2025
Here are four PEG-driven value stocks, WFC, EXEL, DAL and GBX, which qualify our screening criteria.
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
01:16pm, Tuesday, 14'th Jan 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
11:06am, Tuesday, 14'th Jan 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p
Exelixis Provides Preliminary 2024 Results and Outlook for 2025
11:41am, Monday, 13'th Jan 2025
EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:46am, Monday, 13'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 a
The Best Defensive Stocks To Hedge Against Market Uncertainty
05:29pm, Friday, 10'th Jan 2025
2025 has kicked off with an air of uncertainty as investors wait to see how Donald Trump's economic agenda will impact inflation. A potential bear market presents opportunities to reassess portfolios
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
02:45pm, Friday, 10'th Jan 2025
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
04:19pm, Thursday, 09'th Jan 2025
Exelixis' stock has surged over 45% since my "Sell" rating given in March last year, driven by strong performance of cabozantinib, which remains a leading TKI for various cancers. Despite concerns ove
No FDA advisory meeting for Exelixis a positive, says Citi
12:16pm, Thursday, 09'th Jan 2025
Citi keeps a Buy rating on Exelixis with a $38 price target after the company announced that it has been notified by the FDA that the application for Cabometyx for the treatment of previously treated
